BOSTON, June 26,
2024 /PRNewswire/ -- Solarea Bio, a pioneering
biotechnology company focused on developing solutions to improve
human health by harnessing the edible plant microbiome, announces
the appointment of Ilissa Larimore
as Chief Commercial Officer (CCO). Ilissa joins Solarea Bio with
over 20 years of experience in consumer health, personalized
wellness and practitioner engagement to help individuals achieve
optimal health.
Starting her early career as a sales representative with Pfizer
and Metagenics allowed Ilissa to see firsthand the power of
nutritional intervention in aiding the management of chronic
inflammatory conditions. This provided the framework for a
distinguished 14-year career at Metagenics, where she advanced into
various executive roles overseeing commercial operations including
sales and marketing.
"We are thrilled to welcome Ilissa
Larimore to the Solarea Bio team," said Dr. Gerardo V. Toledo, CEO and co-founder of Solarea
Bio. "Her extensive experience in commercial strategy and her
passion for leveraging nutrition and medical foods to improve human
health make her an invaluable addition to our leadership team. We
are confident that Ilissa will play a key role in driving our
commercial success and expanding our impact in the market."
At Solarea Bio, Ilissa will oversee all commercial activities,
driving the strategy for sales, marketing, practitioner
partnerships and industry collaborations. She will focus on
advancing new products to market utilizing Solarea's innovative
technology platform, with a particular focus on medical foods.
"I am honored and excited to join Solarea Bio at such a pivotal
time," said Ilissa Larimore. "The
company's groundbreaking work to develop novel products based on
plant-derived microbes, supported by rigorous clinical development
aligns perfectly with my passion for commercializing medical foods
that focus on the practitioner-patient relationship to improve
health outcomes. I look forward to working with the talented team
at Solarea Bio to bring these innovative solutions to market and
make a meaningful impact on consumers' lives."
Solarea Bio is preparing to enter the commercial stage by
launching its Journa™ consumer health brand. At the same time,
the company will launch its first product - Bondia™ synbiotic,
a new medical food designed to aid in the dietary management of
bone loss in menopausal women. Bondia™ represents the first in
a series of innovative products aimed at addressing unmet needs in
disease management. Additional products, targeting conditions such
as rheumatoid arthritis, are on the horizon, promising to offer
safe and effective solutions for consumers.
About Solarea Bio:
Solarea Bio is a biotechnology company dedicated to harnessing
the power of the edible plant microbiome to develop novel health
solutions. By leveraging advanced scientific research and a deep
understanding of microbial ecosystems, Solarea Bio aims to create
innovative products that improve health and well-being. The
company's mission is to unlock the full potential of its technology
platform to address some of the most pressing health challenges of
our time.
If you are interested in taking the Bondia™ synbiotic or a
healthcare practitioner interested in knowing more about Bondia™,
please send inquires to info@journa.com
For more information about Solarea Bio, please visit
(https://www.solareabio.com).
Media Contact:
media@solareabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ilissa-larimore-appointed-chief-commercial-officer-at-solarea-bio-302182622.html
SOURCE Solarea Bio